ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2034

Resolving Phenotypic and Prognostic Differences in Interstitial Lung Disease Related to Systemic Sclerosis by Computed Tomography-based Radiomics
Abstract Number: 2035

Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design
Abstract Number: 2036

Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
Abstract Number: 2037

Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts
Abstract Number: 2038

Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis
Abstract Number: 2039

Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma
Abstract Number: 2040

Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
Abstract Number: 2041

Disease Features of Systemic Sclerosis Are Associated with Alterations in Gastrointestinal Microbial Composition in Two Independent Cohorts
Abstract Number: 2042

A Low FODMAP Diet Is Not Associated with Decreased GI Symptoms or Changes in GI Microbial Composition in Patients with Systemic Sclerosis
Abstract Number: 2043

Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis
Abstract Number: 2044

Complex, Dynamic Attributes of Antigen-specific T Cells in Rheumatoid Arthritis
Abstract Number: 2045

Resident Memory T Cells in Synovial Tissue Mediate Arthritis Flares
Abstract Number: 2046

Alterations in Circulating CD4+ T Cell Phenotypes in CCP+ Early RA and CCP+ At-risk Individuals by Mass Cytometry
Abstract Number: 2047

Synovial CD8 T Cells in Rheumatoid Arthritis Exhibit High Antigen-independent Cytokine Production and Low Cytotoxic Potential
Abstract Number: 2048

Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].